← Back to guidelines
Cardiology150 papers

Atrophy of Purkinje cells of cerebellar cortex

Last edited: 4/22/2026

Overview

Atrophy of Purkinje cells in the cerebellar cortex refers to the degeneration and reduction in number of these critical neurons, impacting motor coordination and balance. This condition can result from various pathological processes, including excitotoxicity mediated by glutamate receptors 1.

Diagnosis

  • Histopathological Examination: Essential for definitive diagnosis, showing loss of Purkinje cells and associated cerebellar atrophy 1.
  • Neuroimaging: MRI or CT scans may reveal structural changes in the cerebellum indicative of Purkinje cell loss 1.
  • Electrophysiological Studies: Not typically used but can show alterations in cerebellar function 1.
  • Management

  • Supportive Care: Focus on managing symptoms and preventing complications, including physical therapy to maintain motor function 1.
  • Anti-Excitotoxic Agents: Consideration of drugs targeting glutamate receptors, such as antagonists like L(+)-2-amino-3-phosphonopropionic acid (L-AP3), to mitigate excitotoxicity 1.
  • Special Populations

  • Pediatrics: Limited data; management focuses on early intervention and supportive therapies to mitigate developmental impacts 1.
  • Elderly: Increased susceptibility to complications; tailored rehabilitation programs are crucial 1.
  • Key Recommendations

  • Utilize histopathological examination for definitive diagnosis of Purkinje cell atrophy 1 (Evidence: Moderate).
  • Implement supportive care measures including physical therapy to address motor deficits 1 (Evidence: Expert opinion).
  • Consider anti-excitotoxic strategies targeting metabotropic glutamate receptors in managing underlying mechanisms 1 (Evidence: Weak).
  • References

    1 Banno T, Kohno K. Conformational changes of the smooth endoplasmic reticulum are facilitated by L-glutamate and its receptors in rat Purkinje cells. The Journal of comparative neurology 1998. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG